The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
None
Any cancer patient
Cohort
Prospective
Not listed
Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data
Consolidate and annotate data from patients included in a pan-Canadian cohort
Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases
Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases.
Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions
Health technology assessment tools will be used to evaluate the real-world value of precision medicine
Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine
Health technology assessment tools will be used to evaluate the real-world value of precision medicine
Click on the lead sponsor to view all of their trials.
University Health Network, Toronto
Lead sponsor
Princess Margaret Hospital, Canada
Collaborator
Ontario Institute for Cancer Research
Collaborator
Terry Fox Research Institute
Collaborator
Queen's University, Kingston, Ontario
Collaborator
Ottawa Hospital Research Institute
Collaborator
Kingston Health Sciences Centre
Collaborator
Windsor Regional Hospital
Collaborator
University of Windsor
Collaborator
London Health Sciences Centre
Collaborator
London Health Sciences Centre Research Institute
Collaborator
